Accelerate to discover

Homepage>Discover>Assessment of CAR T Cell killing capacity against solid tumors-Thursday, October 20, 2016, 5 pm CEST

Jul 16, 2018

The company producing Avatar, xCELL biosciences have organized a webinar about the tuning of microenvironment to...

How microCT can provide insight into dynamic disease processes webinar

Jun 19, 2018

Professor Vande Velde will describe how high-field MRI and low dose microCT complement each other; where microCT gives...

xCELLIgence webinar: label-free real-time cell analysis technology for Immuno-Oncology

Jun 5, 2018

Cancer immunotherapies harness and enhance the innate power of the immune system to eliminate cancer cells and have...

Photoacoustic Imaging of placental oxygenation

May 16, 2018

Watch the new webinar about photoacoustick imaging presented by Dr. Liliya M. Yamaleyeva, Assistant Professor in the...

Aug 18, 2018

BioFlux webinar: Introducing new plates and capabilities of BioFlux microfluidic system

May 13, 2018

BioFlux biofilm assays can now be performed on the popular catheter material polydimethylsiloxane (PDMS). Silicone...

IncuCyte webinar: advanced 3D cell models providing greater biological insight

Apr 30, 2018

Cancer researchers are increasingly turning to more complex live-cell assay systems that recapitulate key aspects of...

ACEA webinar series: Using xCELLigence RTCA to study biofilms formation

Feb 14, 2018

xCELLigence instruments are revolutionizing pure and applied biofilm research. Beyond gains in efficiency, the...

Aug 18, 2018

NovoCyte live technical webinar: a flow cytometry method for detecting bacteria in water

Feb 9, 2018

Regulatory testing for microbiological water quality is often conducted by growing microbes on agar medium in visible...

Show all topics (10)

Assessment of CAR T Cell killing capacity against solid tumors-Thursday, October 20, 2016, 5 pm CEST

Oct 13, 2016

Nabil Ahmed, M.D., M.P.H. Associate Professor of Pediatrics, Baylor College of Medicine (USA).

Robust CAR design and sensitive yet realistic functional testing will be required in order to improve the efficacy of CAR T cell therapies targeting solid tumors. We have used the xCELLigence Real-Time Cell Analyzer as a high-throughput platform to test multiple CAR components including extracellular domains (including bi-specifics), signaling endo-domains, as well as next-generation CAR T cell products that are inherently resistant to checkpoint blockade. This platform has proven very sensitive to subtle yet longitudinally meaningful differences in CAR design, and has made it possible to evaluate T cell products in a "stress test" that is more representative of early phase trial requirements.

Register now

Webinar

Related technologies: Real-time, Label Free Cell Analysis

Get more info